Crossmark Global Holdings Inc. Takes $2.54 Million Position in Edwards Lifesciences Corporation (NYSE:EW)

Crossmark Global Holdings Inc. acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 23,257 shares of the medical research company’s stock, valued at approximately $2,542,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sabal Trust CO lifted its position in Edwards Lifesciences Corporation by 0.5% during the 2nd quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after buying an additional 14 shares in the last quarter. Alps Advisors Inc. lifted its position in Edwards Lifesciences Corporation by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock worth $603,000 after buying an additional 14 shares in the last quarter. Alexandria Capital LLC lifted its position in Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. Veritable L.P. lifted its position in Edwards Lifesciences Corporation by 1.2% during the 2nd quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock worth $738,000 after buying an additional 71 shares in the last quarter. Finally, First Bank & Trust lifted its position in Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. First Bank & Trust now owns 4,439 shares of the medical research company’s stock worth $525,000 after buying an additional 76 shares in the last quarter. 82.17% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts have commented on EW shares. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. BidaskClub cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Cowen and Company reaffirmed a “buy” rating and issued a $135.00 target price on shares of Edwards Lifesciences Corporation in a report on Thursday, October 12th. BMO Capital Markets reaffirmed a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences Corporation in a report on Friday, September 1st. Finally, Deutsche Bank AG dropped their target price on shares of Edwards Lifesciences Corporation from $122.00 to $115.00 and set a “hold” rating on the stock in a report on Thursday, October 26th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $125.17.

In related news, Director Schack Wesley W. Von sold 1,000 shares of the stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total value of $104,150.00. Following the completion of the transaction, the director now owns 2,622 shares of the company’s stock, valued at approximately $273,081.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total transaction of $594,395.00. The disclosure for this sale can be found here. Insiders have sold a total of 139,580 shares of company stock worth $15,143,994 in the last quarter. 2.13% of the stock is currently owned by company insiders.

Shares of Edwards Lifesciences Corporation (EW) opened at $105.15 on Wednesday. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33. The stock has a market cap of $22,250.00, a P/E ratio of 29.15, a P/E/G ratio of 1.89 and a beta of 0.46. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). The firm had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.68 EPS. analysts forecast that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Crossmark Global Holdings Inc. Takes $2.54 Million Position in Edwards Lifesciences Corporation (NYSE:EW)” was originally posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://weekherald.com/2017/11/15/23257-shares-in-edwards-lifesciences-corporation-ew-acquired-by-crossmark-global-holdings-inc.html.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply